Articles On Avita Medical (ASX:AVH)

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

Aroa Biosurgery forecasts business growth of up to 30% annually with product revenue guidance of NZ$73-$76 million in FY24 New study highlights positive outcomes using Myriad Matrix and Myriad Morcells in complex traumatic wounds Aroa focu...

ASX health sector falls in line with broader markets on macroeconomic factors and global geopolitical tensions Health imaging stock Volpara announces fourth consecutive quarter of operating cashflow Several ASX healthcare names with positi...

ASX-listed Impedimed Limited Pharmaceuticals (ASX:IDP), Avita Medical (ASX:AVH), and Neuren Pharmaceutical (ASX:NEU) lead in share price increase for 2023 while Lumos Diagnostics (ASX: LDX) tops third-quarter rankings.

ASX to open much lower after heavy selloff on Wall Street Tesla, United Airlines and Morgan Stanley tumbled Netflix jumped +12pc after posting best subscriber growth in years   Aussie shares are poised to open lower after a heavy selloff...

Stockhead’s Top 10 at shortly-before-11-ish, produced with mildly heavy heart, as I’m back from and all-too-brief break but would much rather be sitting on the riverbank fishing quietly and ignoring the rest of the world again. Top 10 highl...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Weekly update on stockbroker recommendation, target price, and earnings forecast changes. By Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquari...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

If you're wanting exposure to the energy sector this month, then Santos Ltd (ASX: STO) shares could be the way to do it. That's the view of analysts at Citi, which continue to rate the energy producer as a top option in the sector with ple...

It has been a tough day for Woodside Energy Group Ltd (ASX: WDS) and its fellow ASX energy shares. Investors have been selling off their shares today after oil prices sank during overnight trade. Here's the state of play at the time of wri...

ASX200 drops sharply on Wall Street worry Healthcare only sector to rise Small caps led by Noxopharm, Nimy Resources, Alderan and ECS Botanics   The ASX200 has inched below where it was at the start of 2023, while the Australian dollar...

The S&P/ASX 200 Index (ASX: XJO) is out of form and sinking deep into the red. In afternoon trade, the benchmark index is down 1.3% to 6,942.4 points. Four ASX shares that are falling more than most today are listed below. Here's why...

Regenerative skin restoration company AVITA Medical (ASX:AVH) has announced that its RECELL System won Best Product for the second year in a row at the Annual Meeting of the American Association for the Surgery of Trauma.

Do you want to turn $50,000 into $1 million? It sounds difficult, but long-term investing in ASX shares can help you achieve such dreams. Let's take a look at how you could go from a thousand-naire to a millionaire: Compounding magic The s...

ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P...

ASX healthcare stocks haven’t done so well as a collective over the past 12 months. The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 8% over the past year. By comparison, the market benchmark S&P/ASX 200 Index (ASX: XJO) is u...

Weekly update on stockbroker recommendation, target price, and earnings forecast changes. By Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquari...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Brokers raise target prices for Avita Medical following second quarter results amidst anticipation of exciting prospects in the outlook period. -Avita Medical has beaten consensus three quarters in a row-FY24 guidance upgraded-Recell Go on...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AVH)) - Avita Medical ((BBN)) - Baby Bunting ((NCM)) - Newcrest Mining ((NWS)) - News Corp ((NCK)) - Nick Scali ((PLL)) - Piedmont Lithium ((REA)) - REA Group Check it...

ASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed sinks after delivering a mixed quarterly result including margins contracting Weight loss drug frenzy drives global big pharma plays Nova No...

Futures suggest the ASX is set to open flat this morning, following news that US CPI data had risen for the first time in 13 months to 3.2 per cent. US stocks ended in the green on Wall Street, and on home soil, here are some ASX-listed...

Why do you invest in ASX shares? For many Australians, their end goal is to receive an income without working. It’s not such a crazy dream, though. It’s very realistic, in fact. For those who have managed to save up $50,000 so far, let’s e...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX health stocks have fallen in the past five days in line with broader markets Mach7 wins a US$60 million Veterans contract – the most significant in its history Neuren completes recruitment for Phase II trial of NNZ-2591 in Phelan-McDer...

The S&P ASX 200 was up 1.76% in June, with large caps performing the best and small caps lagging blue chips The S&P/ASX 200 Materials was the best performing sector in June, up 4.8% coming back from April drop An ASX favourite lith...

Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme...

ASX-listed life science companies report a new market capitalisation of $255 billion, with Arovella Therapeutic (ASX:ALA) and Avita Medical (ASX:AVH) topping return rankings for Q1 while Neuren...

Avita Medical’s (ASX:AVH) RECELL System was first approved in the U.S. for the treatment of severe burns in 2018 and prepares, produces, and delivers a regenerative cell suspension, Spray-On Skin Cells, using a small amount of a patient’s o...

Regenerative medicine company AVITA Medical (ASX:AVH) has announced that the US FDA has approved its application for the premarket approval of its RECELL System for the treatment of vitiligo.

AVITA Medical’s (AVH) skin re-pigmentation device gains tick of approval from the USA’s Food and Drug Administration (FDA) to treat patients with vitiligo RECELL is an FDA-approved device which transfers skin cells from pigmented skin to...

Avita Medical shares are down by 4.2% despite positive news as the company announces FDA approval of its breakthrough RECELL skin repair system for vitiligo patients. The post Avita Medical [ASX:AVH] Gains FDA Approval of RECELL Product for...

AVITA receives US FDA premarket approval for its RECELL System Living Cell falls after saying it will enact a temporary pause on pig herd facility Oneview Healthcare signs material deal with NYSE-listed Baxter   Regenerative medicine comp...

AVITA Medical (ASX: AVH) has achieved a 'breakthrough approval' with the US Food and Drug Administration (FDA) by gaining pre-market approval for its RECELL system to treat vitiligo, an autoimmune disease that causes discoloration of the sk...

Spray on skin technology first created in WA will now be used to assist vitiligo patients in the US.

The ASX to open flat today as Wall Street retreated on Friday A Bank of America analyst says current market looks more like 2000 or 2008 Ford says the US is “not quite yet ready” to compete with China in EVs   Australian shares are poised...

Austco Healthcare wins St Paul’s Hospital in Canada worth $7.4m Next Science announced a new CEO AVITA Medical and Genetic Signatures announce new CFOs   Digital health company Austco Healthcare (ASX:AHC) surged by as high as 30% this mor...

Sigma offers very competitive terms to win back Chemist Warehouse contract from Rival EBOS  Pacific Edge slumps ~60% after the US Medicare ended coverage for its Cxbladder test Avita Medical gets US FDA premarket approval for use of its RE...

It has been 30 years in the making, when Dr Fiona Wood and scientist Marie Stoner recognised the potential of tissue engineering to treat burns and a skin culture facility was borne. Their product evolved from cultural sheets of cultural ep...

AVITA Medical (AVH) gains FDA approval to launch its RECELL spray-on skin system to treat full-thickness skin defects This provides relief for a broad label of full-thickness skin defects, including degloving, surgical excision and skin...

ShareCafeTech and Real Estate weigh on market: ASX closes 0.26% lower by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.26 per cent lower at 7,099.70. The drop was mainly driven by losses in the technology and real estate sec...

ShareCafeBond yields surge: ASX 0.09% lower at noon by Peter Milios   At noon, the S&P/ASX 200 is 0.09 per cent lower at 7,111.50, as certain sectors sensitive to interest rates declined, while commodity sectors saw gains due to rising...

Avita receives US FDA approval for RECELL Emyria and Antisense to progress trials Beamtree has won a key contract in Canada   Avita Medical (ASX:AVH) announced that the US FDA has signed off on a premarket approval (PMA) for the use of it...